Dual II China: superior HbA(1c) reductions and weight loss with IDegLira vs insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on basal insulin

Y. Pei, B. R. Agner,Bin Luo,Xiaolin Dong,Dongmei Li,Jun Liu,Lei Liu,Ming Liu,Yibing Lu,Tomoyuki Nishida,Xiangjin Xu,Yiming Mu

DIABETOLOGIA（2020）

引用 6|浏览6

暂无评分

摘要

IDegLira may be an efficacious and well-tolerated treatment intensification option for Chinese people with T2D uncontrolled on basal insulin and OADs. DUAL™ II China; ClinicalTrials.gov Identifier: NCT03175120. This article is protected by copyright. All rights reserved.

查看译文

关键词

Chinese,Insulin degludec/liraglutide,insulin,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要